GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies

被引：0
|
作者：
Hong, Rebecca [1 ]
Edgar, Kyle [1 ]
Song, Kyung [1 ]
Steven, Schmidt [1 ]
Young, Amy [1 ]
Hamilton, Patricia [1 ]
Arrazate, Alfonso [1 ]
De La Cruz, Cecile [1 ]
Chan, Connie [1 ]
Pang, Jodie [1 ]
Salphati, Laurent [1 ]
Belvin, Marcia [1 ]
Nannini, Michelle [1 ]
Staben, Steven [1 ]
Friedman, Lori [1 ]
Sampath, Deepak [1 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD4-14
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
    Turner, Nicolas
    Jhaveri, Komal
    Kalinsky, Kevin
    Loibl, Sibylle
    Loi, Sherene
    Im, Seock-Ah
    Saura, Cristina
    Schmid, Peter
    Schutzman, Jennifer L.
    Stout, Thomas J.
    Lei, Guiyuan
    Hutchinson, Katherine E.
    Thanopoulou, Eirini
    Juric, Dejan
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [32] GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
    Wallin, Jeffrey J.
    Guan, Jane
    Prior, Wei Wei
    Lee, Leslie B.
    Berry, Leanne
    Belmont, Lisa D.
    Koeppen, Hartmut
    Belvin, Marcia
    Friedman, Lori S.
    Sampath, Deepak
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (14) : 3901 - 3911
  • [33] Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Olivera, Mafalda
    Jhaveri, Komal
    Juric, Dejan
    Bedard, Philippe L.
    Cervantes, Andres
    Gambardella, Valentina
    Hamilton, Erika
    Italiano, Antoine
    Kalinsky, Kevin
    Krop, Ian E.
    Schmid, Peter
    Turner, Nicolas
    Varga, Andrea
    Lei, Guiyuan
    Royer-Joo, Stephanie
    Thomas, Piia
    Schutzman, Jennifer L.
    Saura, Cristina
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [34] Combination of class I PI3K inhibitor, GDC-0941, with standard of care therapeutics results in enhanced anti-tumor responses in human cancer models in vitro and in vivo
    Sampath, D.
    Belvin, M.
    Guan, J.
    Edgar, K.
    Wallin, J.
    Prior, W. W.
    Kassees, R.
    Moore, P.
    Patel, S.
    Friedman, L.
    [J]. EJC SUPPLEMENTS, 2008, 6 (12): : 69 - 70
  • [35] Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
    Turner, N.
    Jhaveri, K.
    Kalinsky, K.
    Loibl, S.
    Loi, S.
    Im, S-A.
    Saura, C.
    Schmid, P.
    Schutzman, J. L.
    Stout, T.
    Lei, G.
    Hutchinson, K. E.
    Thanopoulou, E.
    Juric, D.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S391 - S392
  • [36] Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
    Fujimoto, Yumi
    Morita, Tomoko Yamamori
    Ohashi, Akihiro
    Haeno, Hiroshi
    Hakozaki, Yumi
    Fujii, Masanori
    Kashima, Yukie
    Kobayashi, Susumu S.
    Mukohara, Toru
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [37] Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
    Yumi Fujimoto
    Tomoko Yamamori Morita
    Akihiro Ohashi
    Hiroshi Haeno
    Yumi Hakozaki
    Masanori Fujii
    Yukie Kashima
    Susumu S. Kobayashi
    Toru Mukohara
    [J]. Scientific Reports, 10
  • [38] Ispinesib (SB-715992) a kinesin spindle protein (KSP) inhibitor has single agent activity and enhances the efficacy of standard-of-care therapies in pre-clinical models of breast cancer
    Purcell, J. W.
    Reddy, M.
    Davis, J.
    Samayoa, K.
    Vo, C. H.
    Thomsen, K.
    Bean, P. A.
    Rood, K. W.
    Cases, S.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 193S - 193S
  • [39] MEN1611, a PI3K inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01)
    Piccart, Martine
    Hennequin, Audrey
    Borrego, Manuel Ruiz
    Escriva-De-Romani, Santiago
    Williams, Anja
    Rodriguez, Begona Jimenez
    Del Conte, Gianluca
    Howell, Sacha J.
    Palleschi, Michela
    Simonelli, Matteo
    Duhoux, Francois P.
    Tosi, Diego
    Uribe, Bernard Doger De Speville
    Gilarranz, Yolanda Jerez
    Tassone, Pierfrancesco
    Curigliano, Giuseppe
    Waters, Simon
    Aftimos, Philippe
    Wildiers, Hans
    Scartoni, Simona
    Vallespir, Bartomeu Piza
    Shankaraiah, Ram Charan
    Grzegorzewski, Krzysztof
    Habboubi, Nassir
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [40] Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)
    Piccart, M.
    Ruiz Borrego, M.
    Duhoux, F.
    Arkenau, H-T.
    Doger de Speville, B.
    Wildiers, H.
    Campone, M.
    Tosi, D.
    Garcia-Corbacho, J.
    Jimenez, B.
    Escriva-de Romani, S.
    Wardley, A. M.
    Tassone, P.
    Boni, V.
    Jerez, Y.
    Aftimos, P. G.
    Hennequin, A.
    Amair-Pinedo, F.
    Pellacani, A. U. E.
    Laurent, D. O.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S386 - S386
12345